Regarding the patent lawsuit initiated by Illumina against MGI in Hong Kong, the specific impact has yet to be determined.
MGI believes this litigation is an obvious attempt by Illumina to maintain a monopolistic market position and suppress industry development. We intend to vigorously defend our intellectual property and have filed patent litigation against Illumina in U.S. District Courts in California and Delaware.
MGI has an extensive patent portfolio in gene sequencing, with the original goal of “providing the world with the right to another choice.” We will continue delivering effective and affordable healthcare technologies and products worldwide.
